Maxitrol

Neomycin sulfate, Polymyxin B sulfate and Dexamethasone, the active ingredients in Maxitrol, are a combination antibiotic and corticosteroid presented as a 3.5 mg/mL neomycin, 10,000 IU/mL polymyxin B and 0.1 % dexamethasone ophthalmic suspension for topical ocular use. It treats bacterial eye infections with an inflammatory component in patients requiring prescription therapy.

GNH USA supplies Maxitrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxitrol is used for ocular infections and inflammatory conditions where bacterial contamination and inflammation coexist.

- Bacterial conjunctivitis: reduces bacterial load and alleviates conjunctival inflammation. - Keratitis: eradicates pathogenic bacteria and diminishes corneal swelling. - Post‑operative ocular inflammation: controls inflammation while preventing infection after eye surgery. - Anterior uveitis: suppresses intra‑ocular inflammation and limits bacterial involvement. - Other ocular infections with inflammatory component: provides broad‑spectrum antibacterial coverage together with anti‑inflammatory action.

Adverse ocular reactions may occur with topical use of Maxitrol.

Common Side Effects: - Eye irritation or burning sensation. - Stinging or mild pain upon instillation. - Transient blurred vision. - Increased intra‑ocular pressure (mild). - Conjunctival hyperemia.

Serious or Rare Side Effects: - Allergic contact dermatitis or severe hypersensitivity reaction. - Corneal ulceration or secondary infection. - Marked rise in intra‑ocular pressure leading to glaucoma. - Vision loss or severe visual impairment. - Persistent ocular pain or photophobia.

Use Maxitrol only under medical supervision and observe the following precautions.

- Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown risk; consider potential exposure to the infant. - Contact lens wearers: remove lenses before instillation and wait before reinserting. - Concurrent ocular steroids: monitor intra‑ocular pressure regularly. - Prolonged use: may increase risk of secondary infections or cataract formation. - Store at room temperature: keep in original container, protect from light and moisture.

Maxitrol may interact with other ophthalmic agents; consider the following.

Major Interactions (Avoid): - Systemic corticosteroids: additive immunosuppression may increase infection risk. - Other ophthalmic antibiotics: potential antagonism or cumulative toxicity. - Anticholinergic eye drops: may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may heighten ocular irritation. - Glaucoma medications: monitor intra‑ocular pressure for additive effects. - Antiviral eye preparations: assess for reduced antiviral activity.